JP2016501020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501020A5 JP2016501020A5 JP2015544499A JP2015544499A JP2016501020A5 JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- seq
- virus
- influenza
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732809P | 2012-12-03 | 2012-12-03 | |
| US61/732,809 | 2012-12-03 | ||
| PCT/EP2013/075294 WO2014086732A2 (en) | 2012-12-03 | 2013-12-02 | Influenza virus reassortment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501020A JP2016501020A (ja) | 2016-01-18 |
| JP2016501020A5 true JP2016501020A5 (https=) | 2017-01-19 |
| JP6421128B2 JP6421128B2 (ja) | 2018-11-07 |
Family
ID=49713076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544499A Active JP6421128B2 (ja) | 2012-12-03 | 2013-12-02 | リアソータントインフルエンザａウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9708585B2 (https=) |
| EP (1) | EP2925356A2 (https=) |
| JP (1) | JP6421128B2 (https=) |
| KR (1) | KR20150110494A (https=) |
| CN (1) | CN105120893B (https=) |
| AU (2) | AU2013354219A1 (https=) |
| BR (1) | BR112015012380A2 (https=) |
| CA (1) | CA2893429A1 (https=) |
| HK (1) | HK1214959A1 (https=) |
| MX (1) | MX2015006927A (https=) |
| WO (1) | WO2014086732A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150110494A (ko) * | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
| US10323231B2 (en) * | 2015-04-24 | 2019-06-18 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
| HK1254344A1 (zh) | 2015-06-26 | 2019-07-19 | Seqirus UK Limited | 抗原匹配的流感疫苗 |
| GB201602535D0 (en) * | 2016-02-12 | 2016-03-30 | Univ Edinburgh | Improved flu vaccine yield |
| CN111032861B (zh) * | 2017-08-28 | 2023-09-12 | 一般财团法人阪大微生物病研究会 | 重配流感病毒的阶段性制备方法 |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| CN111315407B (zh) * | 2018-09-11 | 2023-05-02 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
| KR101954904B1 (ko) | 2018-10-15 | 2019-03-06 | 남종규 | 복층의 태양광 설치 구조 |
| CN111647610B (zh) * | 2020-06-02 | 2021-09-03 | 扬州大学 | 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| ATE384126T1 (de) | 1998-06-12 | 2008-02-15 | Sinai School Medicine | Interferon induzierende genetisch veränderte attenuierte viren |
| TR200200776T2 (tr) | 1999-09-24 | 2002-06-21 | Smithkline Beecham Biologicals S.A. | Burun içi grip virüsü aşısı. |
| JP4698112B2 (ja) | 2000-03-03 | 2011-06-08 | 一般財団法人化学及血清療法研究所 | 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法 |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| ATE503493T1 (de) | 2001-02-23 | 2011-04-15 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| JP2004536785A (ja) | 2001-02-23 | 2004-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規なワクチン |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| AU2005230708B2 (en) | 2004-04-05 | 2009-01-15 | Zoetis Services Llc | Microfluidized oil-in-water emulsions and vaccine compositions |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| NZ551640A (en) | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| ATE547511T1 (de) | 2004-12-23 | 2012-03-15 | Medimmune Llc | Nichttumorbildende mdck-zellinie zur vermehrung von viren |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| RU2008101367A (ru) | 2005-06-21 | 2009-08-10 | Медиммун, Ллк (Us) | Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| CA2627971A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2007126810A2 (en) * | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| PT2016194E (pt) | 2006-04-19 | 2015-07-20 | Medimmune Llc | Métodos e composições para expressar arn viral de polaridade negativa em células caninas |
| KR101151202B1 (ko) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 수중유 에멀젼 애주번트를 포함하는 백신 |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| WO2008157419A2 (en) * | 2007-06-13 | 2008-12-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| JP5686741B2 (ja) * | 2008-12-16 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | インフルエンザワクチンの生成 |
| EP2233152A1 (en) | 2009-03-24 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade Ag | High growth reassortant influenza A virus |
| EP2573184A1 (en) | 2009-05-21 | 2013-03-27 | Novartis AG | Reverse genetics using non-endogenous POL I promoters |
| SG176178A1 (en) * | 2009-06-25 | 2011-12-29 | Medimmune Llc | Swine influenza hemagglutinin variants |
| WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| AU2011254204B2 (en) * | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
| FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
| KR20150110494A (ko) * | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
-
2013
- 2013-12-02 KR KR1020157016758A patent/KR20150110494A/ko not_active Ceased
- 2013-12-02 WO PCT/EP2013/075294 patent/WO2014086732A2/en not_active Ceased
- 2013-12-02 US US14/648,886 patent/US9708585B2/en active Active
- 2013-12-02 AU AU2013354219A patent/AU2013354219A1/en not_active Abandoned
- 2013-12-02 BR BR112015012380A patent/BR112015012380A2/pt not_active IP Right Cessation
- 2013-12-02 JP JP2015544499A patent/JP6421128B2/ja active Active
- 2013-12-02 CA CA2893429A patent/CA2893429A1/en not_active Abandoned
- 2013-12-02 CN CN201380071503.1A patent/CN105120893B/zh active Active
- 2013-12-02 MX MX2015006927A patent/MX2015006927A/es unknown
- 2013-12-02 HK HK16102968.6A patent/HK1214959A1/zh unknown
- 2013-12-02 EP EP13799527.0A patent/EP2925356A2/en not_active Withdrawn
-
2017
- 2017-06-13 US US15/621,270 patent/US10500266B2/en active Active
-
2018
- 2018-09-19 AU AU2018232956A patent/AU2018232956B2/en active Active
-
2019
- 2019-10-28 US US16/665,104 patent/US20200155666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501020A5 (https=) | ||
| JP2016509864A5 (https=) | ||
| JP2015119730A5 (https=) | ||
| Milián et al. | Current and emerging cell culture manufacturing technologies for influenza vaccines | |
| Thomas et al. | Cell-mediated protection in influenza infection | |
| Cauldwell et al. | Viral determinants of influenza A virus host range | |
| Zhou et al. | Characterization of uncultivable bat influenza virus using a replicative synthetic virus | |
| Horimoto et al. | Enhanced growth of seed viruses for H5N1 influenza vaccines | |
| Bissinger et al. | Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production | |
| JP2019011344A5 (https=) | ||
| Chen et al. | The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response | |
| Feng et al. | Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence | |
| Petiot et al. | Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17 | |
| JP2012511914A5 (https=) | ||
| Jang et al. | Principles underlying rational design of live attenuated influenza vaccines | |
| JP2013179943A5 (https=) | ||
| WO2008156681A2 (en) | Adenoviral vectors for influenza virus production | |
| Neumann et al. | Identification of amino acid changes that may have been critical for the genesis of A (H7N9) influenza viruses | |
| Li et al. | Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome | |
| Abdoli et al. | Comparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production | |
| Johnson et al. | Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs | |
| Silva et al. | Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing | |
| Mostafa et al. | Efficient generation of recombinant influenza a viruses employing a new approach to overcome the genetic instability of HA segments | |
| Mostafa et al. | The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs | |
| Barman et al. | Manipulation of neuraminidase packaging signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influenza vaccine virus yield in eggs |